Seeking Alpha
27 Sept 2026, 09:50 UTC · 1h ago
Verdict
Headline takes no side. We score ANNX +0.40 across two claims — moderately bullish.
+0.40moderately bullish
More positive than 66% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
Annexon expects key readouts from the ARCHER II trial regarding functional vision endpoints in Q4 2026.
Priced inanalysis piece discussing trial endpoints
So whatPositive data within the next quarter would likely trigger a re-rating of the current sector-premium P/B multiple.
More positive than 99% of claims this week
Annexon possesses $209.2M in liquidity and a $200M Oxford Finance facility, providing a cash runway into 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of existing liquidity
So whatThe ~$400M total available capital suggests no dilutive equity financing is required for at least 18 months.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 66% of ticker scores this week
The company has a clear clinical focus on functional outcomes and a cash runway into 2028, though valuation and financing remain risks.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
9h ago
MarketBeat
11h ago
—
ANNX hasn't traded since this ran. Last close $3.64 (Sep 25); the reaction starts at the next open.
ANNX chart →
